Hospital Universitario San Cecilio-ko ikertzaileekin lankidetzan egindako argitalpenak (6)

2024

  1. ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-related cancer

  2. Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion

    European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466

  3. Glucose metabolism outcomes after pituitary surgery in patients with acromegaly

    Pituitary, Vol. 27, Núm. 5, pp. 497-506

  4. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2010

  1. Acromegalia y prolactinomas

    Endocrinologia y Nutricion, Vol. 57, Núm. SUPPL. 1, pp. 7-12

2004

  1. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA)

    European Journal of Endocrinology, Vol. 151, Núm. 4, pp. 439-446